Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Ad5FGF-4 in Patients With Refractory Angina Due to Myocardial Ischemia
NCT02928094 is registered in ClinicalTrials.gov with Angionetics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Ad5FGF-4 in Patients With Refractory Angina Due to Myocardial Ischemia
- Lead sponsor
- Angionetics Inc.
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- January 1, 2023
- Completion date
- December 31, 2024
- Enrollment
- 160 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.